FDA approves Boehringer’s biosimilar adalimumab

Together with Amgen’s biosimilar version (Amjevita, adalimumab-atto) of Abbvie’s autoimmune blockbuster Humira, which received FDA approval last year, Boehringer Ingelheim (BI)’s Cyltezo (adalimumab-adbm) targets a market, in which Humira generated US$10.4bn (globally: 15.9bn) of revenues for last year. Earlier this month, Samsung Bioepis received EU market authorisation for its adalimuab biosimilar Imraldi (adalimumab). As Abbvie is in a patent battle with Boehringer Ingelheim and Amgen, it is still not clear when the biosimilars will be launched. While Abbvie claims that rival biosimilars to Humira couldn’t come to the US market before…